Bazal hücreli karsinomda tek başına veya intralezyonel interferon ile birlikte imikimod kullanımı ile klinik başarı
Loading...
Date
2013-12
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Deri Zührevi Hastalıklar Derneği
Abstract
Bazal hücreli karsinom (BHK), insanlarda en sık görülen deri kanseri tipidir. BHK'ların tedavisinde cerrahi, halen altın standart olarak yerini korumaktadır. Buna rağmen, cerrahiye uygun olmayan ve kozmetik kaygıları olan bireylerde imikimod krem ve intralezyonel interferon (IFN) alfa2b gibi, daha az invaziv, cerrahi olmayan seçenekler de bulunmaktadır. Yalnız başına imikimod ya da imikimod ile kombine olarak interferon alfa-2b ile başarılı bir şekilde tedavi ettiğimiz değişik alt tiplerde 11 BHK vakasını sunduk. 2005-2010 yılları arasında polikliniğimizde histopatolojik olarak BHK oldukları kanıtlanmış, tek başına ya da IFN alfa-2b ile kombine olarak imikimod ile tedavi edilmiş çeşitli alt tiplerdeki hastalar bu rapora dahil edildi. Sunduğumuz 11 hastadan sadece 4 'ü (3 infiltratif, 1 solid tipler) topikal imikimoda ek olarak haftada 3 gün intralezyonel interferon alfa2b 3 milyon IU tedavisi de almıştı. Geri kalan 7 hasta sadece imikimod %5 krem kullanmıştı. Tüm hastalarda bu tedavi seçenekleri ile tam iyileşme sağlandığı görüldü. Bu olgulardaki gözlemlerimiz, İmikimodun sadece yüzeyel değil; infiltratif, solid, nodüler tip BHK'larda da etkili olduğunu düşündürmektedir. İmikimod, sadece yüzeyel değil, aynı zamanda, infiltratif, solid ve nodüler tip BHK'larda da etkili olduğunu düşündürmektedir. İntralezyonel interferon alfa-2b'nin de BHK'larda etkili olduğu ve imikimod ile kombine edildiğinde sinerjistik etki gösterdiği bilinmektedir.
Basal cell carcinoma (BCC) is the most common type of skin cancer in humans. Surgery is still the gold standard for treating BCCs. However, there are also less-invasive, nonsurgical therapies such as imiquimod cream and intralesional interferon (IFN) alpha-2b for patients who are poor surgical candidates and who care about cosmetic outcomes. We report 11 patients with various subtypes of. BCC successfully treated with either imiquimod alone or in combination with interferon alfa-2b. In this paper, we present 11 patients with various subtypes of histopathologically proven BCCs, who were treated with imiquimod or combination of imiquimod and IFN alpha-2b, in our outpatient clinic between 2005 and 2010. Of 11 patients, only 4 patients (3 infiltrative, 1 solid types) had received intralesional interferon alpha-2b at a dose of 3 million IU, 3 times a week combined with topical imiquimod while 7 patients had received only 5% imiquimod cream. All patients were cured with these regimens. Imiquimod is found to be effective not only in superficial, but also in infiltrative, solid, and nodular types. Intralesional interferon alpha-2b is also known to be effective in BCCs and it has a synergistic effect when combined with imiquimod.
Basal cell carcinoma (BCC) is the most common type of skin cancer in humans. Surgery is still the gold standard for treating BCCs. However, there are also less-invasive, nonsurgical therapies such as imiquimod cream and intralesional interferon (IFN) alpha-2b for patients who are poor surgical candidates and who care about cosmetic outcomes. We report 11 patients with various subtypes of. BCC successfully treated with either imiquimod alone or in combination with interferon alfa-2b. In this paper, we present 11 patients with various subtypes of histopathologically proven BCCs, who were treated with imiquimod or combination of imiquimod and IFN alpha-2b, in our outpatient clinic between 2005 and 2010. Of 11 patients, only 4 patients (3 infiltrative, 1 solid types) had received intralesional interferon alpha-2b at a dose of 3 million IU, 3 times a week combined with topical imiquimod while 7 patients had received only 5% imiquimod cream. All patients were cured with these regimens. Imiquimod is found to be effective not only in superficial, but also in infiltrative, solid, and nodular types. Intralesional interferon alpha-2b is also known to be effective in BCCs and it has a synergistic effect when combined with imiquimod.
Description
Keywords
Dermatology, Basal cell carcinoma, Interferon, Imiquimod, Topical imiquimod, Cream, Bazal hücreli karsinom, İnterferon, İmikimod
Citation
Sarıcaoğlu, H. vd. (2013). “Bazal hücreli karsinomda tek başına veya intralezyonel
interferon ile birlikte imikimod kullanımı ile klinik başarı”. Türkderm - Turkish Archives of Dermatology and Venereology, 47(4), 239-242.